Brief: Isofol Says Agent Study Confirms Topline Results
Nov 25 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* FINAL DATA FROM THE AGENT STUDY CONFIRMS TOPLINE RESULTS
* ANALYSIS OF AGENT STUDY'S FINAL DATA CONFIRMED TOPLINE
RESULTS
PRESENTED ON AUGUST 3, 2022
* ISOFOL IS IN PARALLEL CONTINUING TO INVESTIGATE POSSIBLE
FUTURE
PATHS FORWARD FOR COMPANY
Source text for Eikon: ID:nWkr6Rp05z
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical reports no Q2 revenue, net loss widens
Brief: Isofol Medical Q2 Net Income SEK -15.729 Million
Brief: Isofol Medical Adds Clinical Trial Sites To Phase Ib/Ii Arfolitixorin Study In Colorectal Cancer
Sweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million